Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aerpio Pharmaceuticals Inc    ARPO

AERPIO PHARMACEUTICALS INC (ARPO)
My previous session
Most popular
Delayed Quote. Delayed  - 01/18 04:00:00 pm
3.3 USD   +7.84%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
2.89(c) 2.89(c) 2.9099(c) 3.06(c) 3.3(c) Last
103 753 31 205 38 985 147 556 316 915 Volume
-3.67% 0.00% +0.69% +5.16% +7.84% Change
More quotes
Financials (USD)
Sales 2018 20,2 M
EBIT 2018 -10,8 M
Net income 2018 -11,1 M
Finance 2018 69,0 M
Yield 2018 -
Sales 2019 1,67 M
EBIT 2019 -36,7 M
Net income 2019 -36,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 3,22x
Capi. / Sales2019 80,4x
Capitalization 134 M
More Financials
Company
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which... 
More about the company
Latest news on AERPIO PHARMACEUTICALS INC
01/17AERPIO PHARMACEUTICALS : Announces Completion of Patient Dosing in TIME-2b Study..
BU
01/07AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
2018AERPIO PHARMACEUTICALS : to Present at the Stifel 2018 Healthcare Conference
BU
2018AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
2018AERPIO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
2018AERPIO PHARMACEUTICALS : Reports Third Quarter 2018 Financial Results and Provid..
BU
2018AERPIO PHARMACEUTICALS : to Announce Third Quarter 2018 Financial Results and Ho..
BU
2018AERPIO PHARMACEUTICALS : Announces Presentation of Renal Function Data from TIME..
AQ
2018AERPIO PHARMACEUTICALS : Announces Presentation of Renal Function Data from TIME..
BU
2018AERPIO PHARMACEUTICALS : to Present at the Cantor Fitzgerald 2018 Global Healthc..
AQ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart AERPIO PHARMACEUTICALS INC
Duration : Period :
Aerpio Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AERPIO PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,25 $
Spread / Average Target 180%
Managers
NameTitle
Stephen J. Hoffman Chief Executive Officer & Director
Joseph H. Gardner President & Director
Muneer A. Satter Chairman
Michael W. Rogers Chief Financial & Accounting Officer
Kevin Patrick Peters Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AERPIO PHARMACEUTICALS INC94.12%134
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300